Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2020, with a specific reporting date of January 13, 2020. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. These transactions were executed on the London Stock Exchange (XLON) on January 9, 2020.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively details specific share transactions.
| Instrument | Transaction Type | Price (GBP) | Total Volume |
|---|---|---|---|
| Ordinary Shares (25p each) | Acquisition via Dividend Re-investment | 17.9284 | 326 shares |
Note: The total volume of 326 shares represents the aggregate of 11 individual transactions by various executives and their associates.
Material Changes
No material changes to the company's financial position, operations, or strategy are reported in this filing. The document strictly reports routine compliance disclosures regarding share acquisitions resulting from dividend re-investment plans.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with market rules.
Investor Verification Checklist
- Verify that the share acquisitions were executed solely through the Company's Share Reward Plan via dividend re-investment.
- Confirm the transaction date of January 9, 2020, and the execution venue of the London Stock Exchange.
- Note that the filing lists 11 distinct individuals, including the CEO (Ms E Walmsley) and other senior executives, who participated in the plan.
- Understand that this filing does not reflect any change in the company's capital structure or financial health beyond the minor share count increase for these specific individuals.